Vogenx Inc (VOGX:NASDAQ) closed at $18.34 on November 9, 2026, up 5.10% on the day. The stock trades 52.3% below its 52-week high of $38.41 and 41.6% above its 52-week low of $12.95. Over the past year, it gained 34.2%. Vogenx Inc is part of the Health Care sector.
In 62 trading sessions since August 13, 2026, VOGX closed higher on 31 days (50%). Its best day was August 18, 2026 (+25.40%) and its worst was October 1, 2026 (-11.98%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 1 time.
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. Our company was founded in 2021 by experienced leaders with proven expertise developing drugs in the metabolic disease space. Our primary objective is to advance our lead investigational product candidate, mizagliflozin, a selective inhibitor of the sodium-glucose transporter 1, or SGLT1, through clinical development for disorders related to glucose absorption and postprandial dysregulation, through clinical development and towards regulatory approval.
Find more stocks like VOGX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.